Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.
2
1
Q4 and FY23
Highlights
Table of Contents
2 3 4
Company
Business
Shareholder
Overview
Strategy
Information
5
Appendix
Q4 and FY23
1
Highlights
Management Commentary
SUCHETH DAVULURI
"We crossed several significant milestones in FY23 with business driven by ongoing growth in the high margin Specialty and CMS business. The performance of this fiscal reflects the various initiatives we have taken in line with our strategy over the last few years, playing out now. We believe that this puts us in a strong position as we look to consolidate the healthy momentum going forward."
SAHARSH DAVULURI
"We are happy to state that our focus on R&D and project management saw us achieve our highest ever profitability margins in FY23. We executed a number of CMS projects during the year resulting in the business recording significant growth and contributing close to half the Q4 revenues. We expect this momentum to continue in future as well on account of new customers increasingly accepting Neuland as a well regarded CDMO."
5
Attachments
Original Link
Original Document
Permalink
Disclaimer
Neuland Laboratories Ltd. published this content on 11 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 May 2023 10:43:10 UTC.
Neuland Laboratories Limited is an India-based company. The Company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the pharmaceutical and biotech industryâs chemistry needs. It provides solutions across the full range of the pharmaceutical industryâs chemistry requirements, from the synthesis of library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its key molecules include Mirtazapine, an anti-depressant and Levetiracetam, an anti-epileptic agent. The Companyâs product portfolio includes over 100 APIs across 10 diverse therapeutic areas.